Cloud Banner

Healthcare

Image

Global Cycloplegic Agents Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Cycloplegic Agents Market, By Mechanism of Action (Atropine, Cyclopentolate, Cyclomidril, Phenylephrine), Root (Oral, Topical), Indication (Amblyopic Therapy, Palliative Care for Phthisis, Uveitis), Distribution Channel (Hospital, Online, Retail) – Industry Trends and Forecast to 2029.

Cycloplegic Agents Market

Cycloplegic Agents Market Analysis and Size

Cyclopentolate, a common cycloplegic agent, has a peak effect in 20 to 45 minutes and residual effects that last up to 36 hours (Cooper et al. 2000). Mild gastrointestinal discomfort and feeding intolerance are the most common side effects, but more severe atropine-like toxicity with symptoms ranging from vomiting, ileus, hyperthermia, delirium, and grand mal seizures have also been reported.

Data Bridge Market Research analyses that the cycloplegic agents market which is expected to reach at a healthy CAGR during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Cycloplegic Agents Market Scope and Segmentation  

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Mechanism of Action (Atropine, Cyclopentolate, Cyclomidril, Phenylephrine), Root (Oral, Topical), Indication (Amblyopic Therapy, Palliative Care for Phthisis, Uveitis), Distribution Channel (Hospital, Online, Retail)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Pfizer Inc. (U.S.), Henry Schein, Inc (U.S.), Actiza Pharmaceutical Private Limited (India), hameln pharma gmbh (Germany), Sigma Pharmaceuticals, LLC (U.S.), Biomedica (India), Prudence Pharma Chem (India), Heer Pharma Pvt. Ltd. (India), Fresenius Kabi AG (Germany)

Market Opportunities

  • Rising cases of uveitis
  • Growth and expansion of healthcare industry

Market Definition

Cycloplegic agents act by paralysing the iris's sphincter muscle, causing dilation, and by paralysing the ciliary muscle, which inhibits accommodation. Atropine, homatropine, scopolamine, cyclopentolate, and tropicamide are examples of cycloplegic agents. Preventing movement of the iris or ciliary body's dilator and sphincter muscles with cycloplegic drugs often relieves pain in inflammatory conditions such as uveitis and is a standard therapeutic procedure. Furthermore, as a result of the local release of prostaglandins, the iris usually constricts during irritation or inflammation. This makes it easier for adhesions to form with the lens. Cycloplegics also aid in the prevention of this complication.

Global Cycloplegic Agents Market Dynamics

Drivers

  • Increasing cases of uveitis

Pediatric uveitis, which accounts for approximately 10-15% of all uveitis cases, presents unique diagnostic, follow-up, and treatment challenges. The insidious nature of uveitis in childhood, as well as paediatric patients' inability to adequately express their complaints and cooperate with eye examination, can cause a delay in diagnosis. More importantly, paediatric uveitis is more severe and often chronic. All these factors increase the likelihood of complications leading to vision loss. As a result, patients with refractory uveitis require paediatric rheumatology follow-up to begin systemic treatment and to detect underlying rheumatologic disease. These are the certain factors which propel the growth of the market.

  • Rising Demand for Drugs

Three of the new parasympathomimetic-blocking agents appear to be effective cycloplegic drugs appropriate for refraction. These are disubstituted acetic acid esters (Treves and Testa, Ehrenberg, Ramp, Blanchard, and Treves). These drugs have been identified as cyclopentolate (Compound 75 GT), cyclopentolate (Compound 92 GT), and cyclopentolate (Compound 93 GT). Their use in 0.5% solution has previously been reported (cyclopentolate, by Priestley and Medine, and all three compounds by Gettes and Leopold and by Stolzer). Their cycloplegic efficiency appeared to be higher than homatropine but not quite as high as atropine. Furthermore, they have the benefit of a shorter duration of activity and the absence of local or systemic reactions.

Opportunities

  • Rising usage of cycloplegic drugs

Cycloplegic drugs are muscarinic receptor blockers. Atropine, cyclopentolate, homatropine, scopolamine and tropicamide are among them. They are approved for use in cycloplegic refraction (paralysing the ciliary muscle to determine the true refractive error of the eye) and uveitis treatment. These are the factors which is expected to grow of the market.

Restraints/Challenges

  • High cost of cycloplegic agents

High cost of cycloplegic agents and the low adoption rate in emerging and underdeveloped countries will obstruct the market's growth rate. The main disadvantages of cycloplegia are the patients' temporary symptoms of blurred vision and photophobia. The abolition of the accommodation response and an increase in ocular aberrations as a result of dilated pupils cause vision degradation.

This cycloplegic agents market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cycloplegic agents market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Cycloplegic Agents Market Scope

The cycloplegic agents market is segmented on the basis of mechanism of action, root, indication and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mechanism of Action

  • Atropine
  • Cyclopentolate
  • Cyclomidril
  • Phenylephrine

 Root

  • Oral
  • Topical

 Indication

  • Amblyopic Therapy
  • Palliative Care for Phthisis
  • Uveitis

 Distribution Channel

  • Hospital
  • Online
  • Retail

Cycloplegic Agents Market Regional Analysis/Insights

The cycloplegic agents market is analysed and market size insights and trends are provided by country, mechanism of action, root, indication and distribution channel as referenced above.

The countries covered in the cycloplegic agents market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cycloplegic agents market because of the presence of well-developed healthcare infrastructure and favourable reimbursement policies in the region.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 owing to the growing cases of uveitis. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The cycloplegic agents market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cycloplegic agents market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cycloplegic agents market. The data is available for historic period 2010-2020.

Competitive Landscape and Cycloplegic Agents Market Share Analysis

The cycloplegic agents market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cycloplegic agents market.

Some of the major players operating in the cycloplegic agents market are:

  • Pfizer Inc. (U.S.)
  • Henry Schein, Inc (U.S.)
  • Actiza Pharmaceutical Private Limited (India)
  • hameln pharma gmbh (Germany)
  • Sigma Pharmaceuticals, LLC (U.S.)
  • Biomedica (India)
  • Prudence Pharma Chem (India)
  • Heer Pharma Pvt. Ltd. (India)
  • Fresenius Kabi AG (Germany)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

Factors such as increasing cases of uveitisare and increasing personal disposable income are the major growth driving factors.
Pfizer Inc. (U.S.), Henry Schein, Inc (U.S.), Actiza Pharmaceutical Private Limited (India), hameln pharma gmbh (Germany), Sigma Pharmaceuticals, LLC (U.S.), Biomedica (India), Prudence Pharma Chem (India), Heer Pharma Pvt. Ltd. (India), Fresenius Kabi AG (Germany) are the major companies operating in this market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials